KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash from Operations (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Cash from Operations readings, the most recent being 40000000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 61.9% to 40000000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 1714000000.0, a 35.39% increase, with the full-year FY2025 number at 1649000000.0, up 32.24% from a year prior.
  • Cash from Operations hit 40000000.0 in Q1 2026 for Teva Pharmaceutical Industries, down from 1158000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1184000000.0 in Q4 2023 to a low of 145000000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 227000000.0 (2025), compared with a mean of 342000000.0.
  • Biggest five-year swings in Cash from Operations: plummeted 195.92% in 2023 and later surged 13760.0% in 2024.
  • Teva Pharmaceutical Industries' Cash from Operations stood at 973000000.0 in 2022, then rose by 21.69% to 1184000000.0 in 2023, then plummeted by 51.44% to 575000000.0 in 2024, then surged by 101.39% to 1158000000.0 in 2025, then plummeted by 103.45% to 40000000.0 in 2026.
  • The last three reported values for Cash from Operations were 40000000.0 (Q1 2026), 1158000000.0 (Q4 2025), and 369000000.0 (Q3 2025) per Business Quant data.